Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) – Equities research analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Structure Therapeutics in a research report issued to clients and investors on Monday, March 16th. HC Wainwright analyst A. Ghosh now forecasts that the company will earn ($2.27) per share for the year, up from their prior estimate of ($2.34). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Structure Therapeutics’ FY2028 earnings at ($2.37) EPS, FY2029 earnings at ($2.46) EPS and FY2030 earnings at ($2.25) EPS.
GPCR has been the subject of a number of other reports. The Goldman Sachs Group upgraded shares of Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. Morgan Stanley boosted their price target on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Monday. Finally, Stifel Nicolaus boosted their target price on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, Structure Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $110.00.
Structure Therapeutics Stock Down 2.8%
Shares of Structure Therapeutics stock opened at $50.46 on Wednesday. The company’s fifty day simple moving average is $72.57 and its two-hundred day simple moving average is $50.26. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $94.90. The firm has a market cap of $3.57 billion, a PE ratio of -63.87 and a beta of -1.80.
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14).
Institutional Trading of Structure Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Envestnet Asset Management Inc. purchased a new stake in shares of Structure Therapeutics in the 2nd quarter worth approximately $221,000. PNC Financial Services Group Inc. raised its stake in Structure Therapeutics by 29.1% during the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after buying an additional 994 shares during the last quarter. Geode Capital Management LLC raised its stake in Structure Therapeutics by 18.5% during the second quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after buying an additional 8,444 shares during the last quarter. SG Americas Securities LLC bought a new stake in Structure Therapeutics in the second quarter worth $399,000. Finally, DNB Asset Management AS bought a new stake in Structure Therapeutics in the second quarter worth $221,000. 91.78% of the stock is owned by institutional investors.
Structure Therapeutics Company Profile
Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.
The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.
Further Reading
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
